Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Trial Profile

Tolvaptan to Reduce Length of Stay in Hospitalized Patients With Cirrhosis and Hyponatremia

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 06 Jul 2016

At a glance

  • Drugs Tolvaptan (Primary)
  • Indications Hepatic encephalopathy; Hyponatraemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 12 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top